The regenerative biologics marketplace has expanded at a pace exceeding the development of the regulatory framework designed to oversee it. Clinicians assessing stem cell and exosome suppliers encounter a multitude of marketing claims, with limited means to distinguish legitimate credentials from inflated, misused, or fabricated ones [1]. This situation is not merely an abstract compliance exercise.
A single sourcing decision may expose a practice to product liability, risks related to professional licensure, and the substantial possibility of administering a biologic that does not conform to the label’s specifications [2].
This article offers practical guidance for licensed clinicians to identify misleading claims, pose appropriate questions, and source compliant products. It encompasses seven specific red flags, the criteria established by Florida Senate Bill 1768, and a supplier evaluation checklist.
The Regulatory Baseline
Before assessing any supplier, clinicians must comprehend the essential regulatory framework. Currently, there are no exosome products approved by the FDA within the United States [3]. None. Any supplier claiming that their exosomes are “FDA-approved” is providing a factually inaccurate assertion [4].
Similarly, umbilical cord tissue-derived mesenchymal stem cells (UCT-MSCs) are regulated under 21 CFR Part 1271 as human cells, tissues, and cellular and tissue-based products (HCT/Ps), not as approved drugs. Suppliers who confuse FDA registration (a facility credential) with FDA approval (a product license) are either misinformed or are counting on the practitioner being misinformed.
The Food and Drug Administration (FDA) has issued numerous warning letters to exosome suppliers for marketing products as treatments for medical conditions without the necessary regulatory approval [7]. As of 2026, the sole legally permissible pathway for exosome biologics under existing federal legislation is their use in topical cosmetic applications without any disease claims [8]. Additionally, the FDA has issued warning notices to clinics in Florida, California, and Texas for promoting unapproved exosome products [9].
Florida Senate Bill 1768 (2025)
Effective July 1, 2025, Florida Senate Bill 1768 (codified as Sections 458.3245 and 459.0127 of the Florida Statutes) authorizes licensed physicians to administer non-FDA-approved stem cell therapy for orthopedic, wound care, or pain management purposes under defined conditions. The legislation delineates several requirements serving as a framework for clinicians to evaluate suppliers.
- Informed consent is mandatory. Physicians must obtain signed informed consent from patients, clearly stating that the therapy is not FDA-approved [11].
- Sourcing standards are specific. Stem cells must be obtained from facilities that adhere to FDA current Good Manufacturing Practices (cGMP) and are accredited by organizations such as AABB, NMDP, or AATB [12].
- Ethical sourcing is required. The law explicitly prohibits the use of stem cells derived from aborted fetuses [13].
- Post-thaw viability documentation is required. Each treatment lot must include a post-thaw viability analysis report [14].
Clinicians should exercise the utmost caution when evaluating suppliers that cannot demonstrate compliance with these standards, including AATB accreditation, FDA establishment registration, and cGTP compliance.
Seven Red Flags When Evaluating Suppliers
The biologics supply industry exhibits authentic indicators of quality, including AATB accreditation, FDA tissue establishment registration, compliance with cGTP under 21 CFR Part 1271, NTA-verified particle counts, and dual-laboratory Certificates of Analysis [15]. Any deviations from this framework may serve as potential warning signs.
1. “FDA-Approved” Exosome or Stem Cell Products.
This is the most frequently encountered assertion (and the most likely to disqualify) in the market. Currently, no exosome products are approved by the FDA in the United States [3]. Any supplier asserting this claim is either uninformed or intentionally misrepresenting the regulatory framework [16].
2. Misuse of “cGMP” for Tissue-Based Products.
cGMP and cGTP are not interchangeable. cGMP pertains to drug products; cGTP, under 21 CFR Part 1271, pertains to human cell and tissue-based products, including UCT-MSCs and exosomes [17]. A supplier marketing these products as “cGMP-manufactured” is conflating two distinct regulatory categories [18].
3. Single-Lab Certificates of Analysis (COAs).
A Certificate of Analysis (COA) issued by the manufacturer’s internal laboratory does not constitute independent verification [19]. The credibility standard requires dual-laboratory testing: manufacturer quality control (QC) combined with independent third-party verification on the same batch [20]. If a supplier can only provide a single-laboratory COA on their own letterhead, the practitioner is expected to rely on a self-assessed report [21].
4. Particle Counts without NTA Verification.
Statements such as “60 billion exosomes per vial” lack significance without the details of the measurement methodology. Nanoparticle Tracking Analysis (NTA) is acknowledged as the industry standard for quantifying extracellular vesicle concentration and size distribution [22]. Absent NTA documentation on the Certificate of Analysis (COA), particle counts may be exaggerated, estimated, or purely hypothetical [23].
5. Vague or Missing Source Tissue Documentation.
Not all umbilical cord tissue is equivalent. Reputable suppliers meticulously document the tissue source (Wharton’s Jelly), donor screening procedures (including HIV, hepatitis B, and C testing, among others), pregnancy history, country of origin, and the number of population doublings [24]. A supplier who is unable to disclose these variables is offering tissue of indeterminate provenance [25].
6. Mechanism-of-Action and Disease Claims in Marketing.
Under the FDA framework, mechanism-of-action claims are classified as therapeutic claims, effectively transforming a non-drug biologic into an unapproved drug [26]. Claims such as “anti-inflammatory,” “immune modulating,” “stem cell activating,” “tissue regenerating,” or any indication designated by a disease name are considered explicit violations of regulatory standards [27].
7. No AATB Accreditation or FDA Tissue Establishment Registration.
Florida’s HB 1768 explicitly designates AATB as an approved accrediting organization [28]. A supplier lacking AATB accreditation operates outside the acknowledged regulatory framework, as explicitly identified by state legislatures [29]. Registration of tissue establishments with the FDA constitutes a distinct obligation, verifiable through the FDA’s publicly accessible database [30].
Supplier Evaluation Checklist
| Red Flag Category | What to Ask Instead |
| “FDA-approved” exosomes | “Is your facility FDA-registered as a tissue establishment, and are your products positioned as research-grade biologics for topical professional use?” |
| Misuse of “cGMP” for tissue products | “Is your processing lab cGTP-compliant under 21 CFR Part 1271, and can you provide documentation of your tissue establishment registration?” |
| Single-lab COAs | “Can I see a sample dual-lab Certificate of Analysis showing both manufacturer QC and independent third-party verification on the same lot?” |
| Particle counts without NTA. | “Is the particle count NTA-verified per lot, and does the lot-specific COA document the measurement method?” |
| Vague source tissue | “Is the tissue first-pregnancy Wharton’s Jelly, domestically sourced, with full donor screening documentation and a documented population doubling specification?” |
| Mechanism/disease claims | “Can you show me how your product is positioned in marketing materials, and confirm you do not make mechanism-of-action or disease claims?” |
| No AATB accreditation | “What is your AATB accreditation status, and can you provide your FDA tissue establishment registration number for verification?” |
If a supplier is unable to provide documentation for any item on this list, it constitutes a sourcing decision that warrants escalation. If the supplier is unable to produce documentation for three or more items, the supplier should be considered for replacement.[31]
RegenOMedix: Documented Compliance in Action
RegenOMedix sources stem cell and exosome products processed in FDA-registered facilities. These cleanroom facilities adhere to current Good Manufacturing Practices and are accredited by organizations recognized under Florida statute, including the American Association of Tissue Banks (AATB). All products are supported by the clinical documentation and compliance credentials required for licensed medical practices.
RegenOMedix is recruiting participants for a clinical application of its exosome products that has received approval from the Institutional Review Board (IRB). Additionally, the company offers a specialized patient-tracking portal designed to facilitate structured data collection and outcome monitoring.
References
[1] “7 Red Flags When Sourcing Exosomes & Stem Cells: A Buyer’s Guide for Licensed Practitioners,” Stem Nova Network, 2026. [Online]. Available: https://www.stemnovanetwork.com/blogs/exosome-stem-cell-resources-for-medical-professionals/red-flags-sourcing-exosomes-stem-cells-buyers-guide-licensed-practitioners
[2] “FDA Increases Flexibility on Requirements for Cell and Gene Therapies to Advance Innovation,” FDA, Jan. 2026. [Online]. Available: https://www.fda.gov/news-events/press-announcements/fda-increases-flexibility-requirements-cell-and-gene-therapies-advance-innovation
[3] FDA, “Public Safety Notification on Exosome Products,” Dec. 2019. [Online]. Available: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products
[4] FDA, “Platinum Biologics LLC – Warning Letter,” Aug. 2025. [Online]. Available: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/platinum-biologics-llc-705090-08152025
[5] “Current Good Tissue Practice (CGTP) and Additional Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps),” FDA, May 2025. [Online]. Available: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-tissue-practice-cgtp-and-additional-requirements-manufacturers-human-cells-tissues-and
[6] “How to Source Topical Cosmetic Exosome Biologics into Your Practice,” Stem Nova Network, 2026. [Online]. Available: https://www.stemnovanetwork.com/blogs/exosome-stem-cell-resources-for-medical-professionals/how-to-add-exosome-therapy-to-your-clinic-or-medspa-2026-complete-guide
[7] “Know Your Supplier: A Buyer’s Guide to Vetting Exosome & Stem Cell Companies,” Stem Nova Network, 2026. [Online]. Available: https://www.stemnovanetwork.com/blogs/exosome-stem-cell-resources-for-medical-professionals/know-your-supplier
[8] Federal Trade Commission, “Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments,” Jan. 2025. [Online]. Available: https://www.ftc.gov/news-events/news/press-releases/2025/01/stem-cell-institute-co-founders-companies-banned-marketing-stem-cell-treatments-ordered-pay-more-51
[9] “Florida’s New Stem Cell Law: What It Signals for Physicians, Patients and the Future of Regenerative Medicine,” MedCity News, Aug. 2025. [Online]. Available: https://medcitynews.com/2025/08/floridas-new-stem-cell-law-what-it-signals-for-physicians-patients-and-the-future-of-regenerative-medicine/
[10] Florida Senate, “CS/CS/SB 1768 (2025) – Bill Analysis,” Apr. 2025. [Online]. Available: https://www.flsenate.gov/Session/Bill/2025/1768/Analyses/2025s01768.pre.ahs.PDF
[11] Florida Senate, “SB 1768 – 2025 Session Summary,” 2025. [Online]. Available: https://www.flsenate.gov/Session/Bill/2025/1768
[12] “AATB Accreditation, Federal Compliance, and the State-by-State Legal Landscape for Stem Cell Biologics in 2026,” Stem Nova Network, 2026. [Online]. Available: https://www.stemnovanetwork.com/blogs/exosome-stem-cell-resources-for-medical-professionals/aatb-accreditation-federal-compliance-and-the-state-by-state-legal-landscape-foraatb-accreditation-state-stem-cell-laws-licensed-practitioners-2026
[13] “Exosome Therapies – Karli Health,” Karli Health, Sep. 2025. [Online]. Available: https://www.karlihealth.com/exosome-therapies
[14] “AATB Accreditation – American Association of Tissue Banks,” AATB. [Online]. Available: https://www.aatb.org/accreditation
[15] “RegenOMedix™ Receives IRB Approval for Clinical Use of Ascellos™ Stem Cells and Therapeutic Exosomes,” RegenOMedix, Feb. 2026. [Online]. Available: https://regenomedix.com/regenomedix-receives-irb-approval/
